PBM Act
- Bill Number
- S. 4509
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-13: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2026-06-01T12:29:01Z
AI-Generated Summary
Summary of S. 4509: Patients Before Monopolies Act (PBM Act)
Purpose
This legislation seeks to prohibit common ownership between pharmacy benefit managers (PBMs) and pharmacies to reduce conflicts of interest in the pharmaceutical supply chain. It aims to promote competition, lower prescription drug costs for patients and health plans, and protect independent pharmacies by requiring structural separation of vertically integrated health companies.
Key Provisions
- Ownership Prohibition: It is unlawful for any person or entity to own, operate, control, or direct both a pharmacy and either an insurance company or a PBM.
- Divestment Requirement: Entities violating the ownership rule must sell off their pharmacy operations within one year of the Act's enactment.
- Enforcement Mechanisms:
- The Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division have authority to enforce the law, including issuing guidance on divestment milestones and imposing monthly profit transfers to escrow for non-compliance.
- A divestiture trustee may oversee sales if deadlines are missed.
- Civil Actions:
- Authorized parties (including the HHS Inspector General, state attorneys general, and private individuals) may sue in federal or state courts for violations.
- Successful private lawsuits can result in treble damages, attorney fees, and other relief.
- Courts may order cessation of violations, divestment, and disgorgement of revenue from pharmacy sales during the violation period.
- FTC and DOJ Oversight:
- Divestments must be reported under the Clayton Act, regardless of standard thresholds.
- The agencies review divestitures for effects on competition and may block actions that harm the public interest.
- Additional Authorities: The FTC may issue rules to implement the Act, and quarterly compliance reports are required to Congress.
Significant Changes to Existing Law
- Introduces a new structural separation rule banning vertical integration between pharmacies and PBMs or insurers, which is not currently prohibited under federal antitrust statutes.
- Creates a private right of action for individuals harmed by violations, allowing treble damages (an expansion beyond typical antitrust remedies in some contexts).
- Mandates reporting and review of divestitures without regard to usual monetary thresholds in the Clayton Act.
- Establishes specific penalties, such as profit escrow transfers and trustee oversight, for failure to comply with divestment timelines.
Potential Impacts
- On Government Agencies: Increases responsibilities for the FTC, DOJ Antitrust Division, and HHS Inspector General in enforcement, reviews, and reporting; may require additional resources for oversight and rulemaking.
- On Citizens: Could lead to greater competition among pharmacies, potentially reducing drug prices and improving access for patients; may support independent pharmacies facing contract pressures.
- On Taxpayers and Health Plans: Aims to prevent profit shifting that circumvents Medical Loss Ratio requirements, potentially lowering costs in public and private insurance programs.
- No direct effects on international relations are addressed in the legislation.
Main Stakeholders Affected
- Pharmacy benefit managers and their parent companies.
- Retail, mail-order, specialty, and other pharmacies (including those affiliated with larger health conglomerates).
- Health insurance companies and health plans.
- Patients, consumers, and independent pharmacies.
- Federal agencies (FTC, DOJ, HHS).
- State attorneys general.
- Taxpayers and health plan enrollees.
Notable Legal, Constitutional, or Political Implications
- Relies on Congress's authority under the Commerce Clause (Article I, Section 8) to regulate interstate commerce involving national health conglomerates.
- Includes a severability clause to preserve the Act if any part is found invalid.
- Provides for injunctive relief, disgorgement, and a right to jury trial in civil actions.
- Enhances antitrust tools for addressing vertical integration and self-preferencing in the health care sector, with potential to influence future merger reviews.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Hawley, Josh [R-MO], Sen. Fetterman, John [D-PA], Sen. Marshall, Roger [R-KS]
Recent Actions
- 2026-05-13: Read twice and referred to the Committee on the Judiciary.
- 2026-05-13: Introduced in Senate
Bill Versions
- Patients Before Monopolies Act — issued 2026-05-13 — PDF (14 pages)